BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring
Go back to BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, RestructuringMERRIMACK PHARM (NASDAQ: MACK) | Delayed: 14.75 +0.03 (0.20%) | |||||
---|---|---|---|---|---|---|
Previous Close | $14.72 | 52 Week High | $9.63 | |||
Open | $14.75 | 52 Week Low | $4.39 | |||
Day High | $14.80 | P/E | N/A | |||
Day Low | $14.72 | EPS | $-1.24 | |||
Volume | 129,206 |